Home / Pharmaceuticals / Premature Ejaculation Treatment Market By Drug Class (Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors, Others), By Route Of Administration (Oral Route, Topical Route) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Premature Ejaculation Treatment Market By Drug Class (Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors, Others), By Route Of Administration (Oral Route, Topical Route) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Published: Aug 2018 | Report Code: 59268-08-18

Industry Outlook

The premature ejaculation treatment market is set to reach US$ 3,541.4 Mn by 2026 from US$ 1,666.1 Mn in 2017 showcasing progressive growth at a compound annual growth rate (CAGR) of 8.8% during the forecast period from 2018 to 2026. According to the research survey conducted by the International Journal of Impotence Research (IJIR), 30% adult men throughout the globe suffer with premature ejaculation. The prevalence rate of premature ejaculation varies across geographical and socio-cultural population. Premature ejaculation has been understood to cause a negative impact on the sexual satisfaction in men and their sexual partners.

People suffering with premature ejaculation are less likely to seek medical help, thus making it of utmost importance to raise awareness and acceptance of this disorder in patients and physicians. Existence of developed healthcare infrastructure and rising prevalence of premature ejaculation disorder drive the market growth in North America. Presence of matured generic drug market and increasing awareness of premature ejaculation propel the market growth in Asia Pacific.

Market Synopsis

Premature Ejaculation Treatment Market

Get a sample copy for more information

Impressive pharmacodynamic properties exerted by SSRI’s make it drug of first choice for premature ejaculation treatment

Selective serotonin reuptake inhibitors are prescribed as the first line drug therapy for treatment of premature ejaculation. The mechanism of action involved is delayed ejaculation due to limited reabsorption of serotonin at the presynaptic neuron cells and increasing the serotonin levels at the postsynaptic receptors. The drugs prescribed as SSRI’s are sertraline, paroxetine, fluoxetine and citalopram. Topical anesthetic agents are set to project impressive growth during the forecast period 2018 to 2026. Currently Fortacin™ a eutectic mixture of Lidocaine and Prilocaine is being used as a topical aerosol formulation to decrease sensitivity of glans penis and increase the intravaginal ejaculation latency time. The topical anesthetic agents have better patient compliance and excellent sexual satisfaction in patients suffering with premature ejaculation.

Premature Ejaculation Treatment Market

Get a sample copy for more information

Faster onset on action and low price makes oral route of administration popular among patients suffering with acute premature ejaculation

Prescribed drugs such as SSRI’s, tricyclic antidepressant, Phosphodiesterase type 5 inhibitors and beta-adrenergic blockers are taken by oral route of administration. Quick response time and availability at low price increases the popularity of oral route among patients suffering with acute premature ejaculation. Topical route is to register magnificent growth during the forecast period 2018 to 2026 due to better patient compliance and excellent climax control by delaying the intravaginal ejaculation.

Premature Ejaculation Treatment Market

Get a sample copy for more information

Rise in psychotropic drug use and lack of constructive attitude towards sex determines Asia Pacific market growth

In the present scenario North America holds the largest regional market in premature ejaculation treatment market with 41.5% share. Rising incidence of relationship stress, depression and anxiety in younger population and increasing number of people suffering with illicit drug abuse are responsible for premature ejaculation issues in North America. Domicile of market leaders such as GlaxoSmithkline Plc and Teva Pharmaceutical Industries Ltd., and adherence to effective treatment guidelines drives the premature ejaculation treatment market in Europe. Asia Pacific serves as a lucrative market for premature ejaculation treatment. The factors responsible for the market growth are rise in psychotropic drug use and lack of constructive attitude towards sex. Latin America and Middle East and Africa will project moderate growth during the forecast period 2018 to 2026 on account of developing healthcare infrastructure and rising public health awareness regarding premature ejaculation.

Premature Ejaculation Treatment Market

Historical & Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

Latest market trends for the report premature ejaculation treatment market were determined by quantitative analysis. The market segment comprises of drug class, route of administration and geography.

ATTRIBUTE DETAILS
Research Period  2016-2026
Base Year 2017
Forecast Period  2018-2026
Historical Year  2016
Unit  USD Million
Segmentation

 By Drug Class (2016–2026; US$ Mn)
 • Selective Serotonin Uptake Inhibitors
    o Paroxetine
    o Sertraline
    o Citalopram
    o Fluoxetine
 • Tricyclic Antidepressant
    o Clomipramine
 • Topical Anesthetic Agent
    o Lidocaine/Prilocaine
    o Benzocaine
 • Phosphodiesterase Type 5 Inhibitors
    o Sildenafil
    o Vardenafil
 • Others (Beta-adrenergic Blocker, Opioid Analgesic)

 By Route of Administration (2016–2026; US$ Mn)
 • Oral
 • Topical

 Geography Segment (2016–2026; US$ Mn)
 • North America (United States and Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (China, Japan, Rest of Asia Pacific)
 • Latin America (Brazil, Mexico, Rest of Latin America)
 • Middle East and Africa (GCC, Rest of MEA)

The premature ejaculation market comprises of branded and generic drugs which are prescribed according to the disease prognosis. Inorganic and organic market growth strategies are being employed by market leaders to generate revenue in premature ejaculation treatment market. Quantitative analysis is a very useful tool for mapping the drivers, restraints and opportunities prevalent in the premature ejaculation treatment market. Diverse product portfolio gives a better understanding of the competition prevalent in the market. The pharmaceutical companies commanding the premature ejaculation treatment market are Absorption Pharmaceuticals, AstraZeneca, Allergan Plc, Bayer AG, Eli Lilly & Company, GlaxoSmithkline Plc, Innovus Pharmaceuticals, Merck & Co., Inc., Pfizer, Inc. and Teva Pharmaceutical Industries Ltd.

Key questions answered in this report

  • Who are the market leaders steering the premature ejaculation treatment market?
  • What will be the compound annual growth rate and market estimation for premature ejaculation treatment market?
  • What are the organic and inorganic market strategies adopted by key players?
  • What are the DRO’s for the premature ejaculation treatment market?
  • What is the disease prognosis and how it contributes to market growth?
  • Which is the leading and fastest growing route of administration segment for premature ejaculation treatment market?
  • Which is the largest and fastest growing drug class segment for premature ejaculation treatment market?
  • Which is the largest and fastest growing regional segment for premature ejaculation treatment market?
  • What drugs are being prescribed and treatment guidelines postulated for the treatment of premature ejaculation?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global PET Market Portraiture
2.2. Global PET Market, by Drug Class, 2017 (US$ Mn)
2.3. Global PET Market, by Route of Administration, 2017 (US$ Mn)
2.4. Global PET Market, by Geography, 2017 (US$ Mn)

Chapter 3. Premature Ejaculation Treatment (PET) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global PET Market, by Key Players, 2017

Chapter 4. Global Premature Ejaculation Treatment (PET) Market, by Drug Class
4.1. Overview
4.2. Selective Serotonin Reuptake Inhibitor
4.2.1. Paroxetine
4.2.2. Sertraline
4.2.3. Citalopram
4.2.4. Fluoxetine
4.3. Tricyclic Antidepressant
4.3.1. Clomipramine
4.4. Topical Anesthetic Agent
4.4.1. Lidocaine/Prilocaine
4.4.2. Benzocaine
4.5. Phosphodiesterase Type 5 Inhibitors
4.5.1. Sildenafil
4.5.2. Vardenafil
4.6. Others (Beta-adrenergic Blockers, Analgesic Opioids)

Chapter 5. Global Premature Ejaculation Treatment (PET) Market, by Route of Administration
5.1. Overview
5.2. Oral Route
5.3. Topical Route

Chapter 6. Global Premature Ejaculation Treatment (PET) Market, by Geography
6.1. Overview
6.2. North America PET Market Analysis, 2016 – 2026
6.2.1. North America PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.2.2. North America PET Market, by ROA, 2016 – 2026 (US$ Mn)
6.2.3. North America PET Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe PET Market Analysis, 2016 – 2026
6.3.1. Europe PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.3.2. Europe PET Market, by ROA, 2016 – 2026 (US$ Mn)
6.3.3. Europe PET Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Premature Ejaculation Treatment Drugs Market Analysis, 2016 – 2026
6.4.1. Asia Pacific PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.4.2. Asia Pacific PET Market, by ROA, 2016 – 2026 (US$ Mn)
6.4.3. Asia Pacific PET Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America PET Market Analysis, 2016 – 2026
6.5.1. Latin America PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.5.2. Latin America PET Market, by ROA, 2016 – 2026 (US$ Mn)
6.5.3. Latin America PET Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa PET Market Analysis, 2016 – 2026
6.6.1. MEA PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.6.2. MEA PET Market, by ROA, 2016 – 2026 (US$ Mn)
6.6.3. MEA PET Market, by Region, 2016 – 2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Absorption Pharmaceuticals
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. AstraZeneca
7.3. Allergan, Plc
7.4. Bayer AG
7.5. Eli Lilly & Company
7.6. GlaxoSmithkline, Plc
7.7. Innovus Pharmaceutical
7.8. Merck & Co., Inc.
7.9. Pfizer, Inc.
7.10. Teva Pharmaceutical Industries Ltd.

* PET - Premature Ejaculation Treatment

FIG. 1 Premature Ejaculation Treatment (PET) Market: Research Methodology
FIG. 2 PET Market Segmentation
FIG. 3 Global PET Market, by Drug Class, 2017 (US$ Mn)
FIG. 4 Global PET Market, by ROA, 2017 (US$ Mn)
FIG. 5 Global PET Market, by Geography, 2017 (US$ Mn)
FIG. 6 Attractive Investment Proposition: by Geography, 2017
FIG. 7 Competitive Analysis: Global PET Market, by Key Players, 2017
FIG. 8 Global Paroxetine Market for PET, 2016 – 2026 (US$ Mn)
FIG. 9 Global Sertraline Market for PET, 2016 – 2026 (US$ Mn)
FIG. 10 Global Citalopram Market for PET, 2016 – 2026 (US$ Mn)
FIG. 11 Global Fluoxetine Market for PET, 2016 – 2026 (US$ Mn)
FIG. 12 Global Tricyclic Antidepressant Market for PET, 2016 – 2026 (US$ Mn)
FIG. 13 Global Lidocaine/Prilocaine Market for PET, 2016 – 2026 (US$ Mn)
FIG. 14 Global Benzocaine Market for PET, 2016 – 2026 (US$ Mn)
FIG. 15 Global Sildenafil Market for PET, 2016 – 2026 (US$ Mn)
FIG. 16 Global Vardenafil Market for PET, 2016 – 2026 (US$ Mn)
FIG. 17 Global Other Drug Class Market for PET, 2016 – 2026 (US$ Mn)
FIG. 18 Global Oral Route Market for PET, 2016 – 2026 (US$ Mn)
FIG. 19 Global Topical Route Market for PET, 2016 – 2026 (US$ Mn)
FIG. 20 U.S. PET Market, 2016 – 2026 (US$ Mn)
FIG. 21 Canada PET Market, 2016 – 2026 (US$ Mn)
FIG. 22 U.K. PET Market, 2016 – 2026 (US$ Mn)
FIG. 23 Germany PET Market, 2016 – 2026 (US$ Mn)
FIG. 24 Rest of Europe PET Market, 2016 – 2026 (US$ Mn)
FIG. 25 China PET Market, 2016 – 2026 (US$ Mn)
FIG. 26 Japan PET Market, 2016 – 2026 (US$ Mn)
FIG. 27 Rest of Asia Pacific PET Market, 2016 – 2026 (US$ Mn)
FIG. 28 Brazil PET Market, 2016 – 2026 (US$ Mn)
FIG. 29 Mexico PET Market, 2016 – 2026 (US$ Mn)
FIG. 30 Rest of Latin America PET Market, 2016 – 2026 (US$ Mn)
FIG. 31 GCC PET Market, 2016 – 2026 (US$ Mn)
FIG. 32 Rest of Middle East and Africa PET Market, 2016 – 2026 (US$ Mn)

TABLE 1 Global Premature Ejaculation Treatment (PET) Market Portraiture
TABLE 2 Global PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 3 Global SSRI Market for PET, by Drug Class, 2017 (US$ Mn)
TABLE 4 Global Topical Anesthetic Agents Market for PET, by Drug Class, 2017 (US$ Mn)
TABLE 5 Global Phosphodiesterase Type 5 Inhibitors Market for PET, by Drug Class, 2017 (US$ Mn)
TABLE 6 Global PET Market , by ROA, 2016 – 2026 (US$ Mn)
TABLE 7 Global PET Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 8 North America PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 9 North America PET Market, by ROA, 2016 – 2026 (US$ Mn)
TABLE 10 North America PET Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 11 Europe PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 12 Europe PET Market, by ROA, 2016 – 2026 (US$ Mn)
TABLE 13 Europe PET Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 14 Asia Pacific PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 15 Asia Pacific PET Market, by ROA, 2016 – 2026 (US$ Mn)
TABLE 16 Asia Pacific PET Market, by Country/Region, 2015 – 2025 (US$ Mn)
TABLE 17 Latin America PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 18 Latin America PET Market, by ROA, 2016 – 2026 (US$ Mn)
TABLE 19 Latin America PET Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 20 Middle East and Africa PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 21 Middle East and Africa PET Market, by ROA, 2016 – 2026 (US$ Mn)
TABLE 22 Middle East and Africa PET Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 23 Absorption Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 AstraZeneca: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 Allergan, Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Eli Lilly & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 GlaxoSmithkline, Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Innovus Pharmaceutical: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 30 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 31 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 32 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Our Clients